EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Antibiotic and Nonantibiotic Drugs Associated With Clostridioides difficile Infection Risk: a Pharmacopoeia-Wide Case-Cohort Study

Kevin A Brown iD, Bryan Coburn iD, Alejandro Hernandez iD, Bradley J Langford iD, Valerie Leung iD, Derek MacFadden, Ashley M Rooney, Kevin L Schwartz, Nick Daneman

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag001 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Kevin A Brown und 8 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Ontario, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Clostridium Infections, Clostridioides difficile. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clostridioides difficile infection (CDI) is principally precipitated by antibiotics, due to their disruption of gut commensal bacteria. The comparative role of nonantibiotic drugs is poorly characterized.

Methods

We examined the contribution of antibiotic and nonantibiotic drugs to CDI risk among residents age >65 years old and not hospitalized in the prior 30 days, between 2018 and 2023. The study used a case-cohort study design, with logistic regression analysis. The case definition consisted of first incident CDI, identified using comprehensive C. difficile testing, hospitalization, and treatment data. Outpatient oral drug exposures were measured in a 1–90-day window prior to case and control days. Adjusted regression models included covariates for age, sex, year and quarter, region, comorbid conditions, healthcare exposures, and drug exposures.

Results

Among 16 196 CDI case patients and 549 831 controls, 335 drugs were included. After adjustment, the antibiotics amoxicillin-clavulanate (odds ratio [OR], 6.05 [95% confidence interval (CI), 5.69–6.43]), clindamycin (16.83 [15.53–18.24]), ciprofloxacin (3.83 [3.59–4.09]), and cephalexin (3.05 [2.86–3.25]), were the largest contributors to CDI risk. Nonantibiotic drugs pantoprazole (OR, 1.33 [95% CI, 1.27–1.39]) and ferrous fumarate (1.71 [1.61–1.82]) were the next largest. Metformin had a protective association (OR, 0.67 [95% CI, .63–.72]). In a meta-regression on a subset of 182 drugs, in vitro anticommensal activity was positively associated with CDI risk (P < .001).

Conclusions

This study provides insights into CDI etiology and avenues for stewardship and drug repurposing to combat CDI and antimicrobial resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsClostridium InfectionsClostridioides difficileHumansAgedFemaleMaleAged, 80 and overCase-Control StudiesRisk FactorsCohort Studies

Stichwörter der Autor:innen

Clostridium difficileantibiotic-associated diarrheadrug surveillancemicrobiome

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Public Health Ontario, Toronto, Ontario, Canada.
  • Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
  • ICES, Toronto, Ontario, Canada.
  • Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Toronto General Hospital Research Institute, Toronto, Ontario, Canada.
  • Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

ORCID-Profile: Kevin A Brown, Bryan Coburn, Alejandro Hernandez, Bradley J Langford, Valerie Leung

Zitieren

APA

Brown, K. A., Coburn, B., Hernandez, A., Langford, B. J., Leung, V., MacFadden, D., Rooney, A. M., Schwartz, K. L., & Daneman, N. (2026). Antibiotic and Nonantibiotic Drugs Associated With Clostridioides difficile Infection Risk: a Pharmacopoeia-Wide Case-Cohort Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag001

Vancouver

Brown KA, Coburn B, Hernandez A, Langford BJ, Leung V, MacFadden D, et al. Antibiotic and Nonantibiotic Drugs Associated With Clostridioides difficile Infection Risk: a Pharmacopoeia-Wide Case-Cohort Study. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag001

BibTeX
@article{Brown2026,
  author = {Brown, Kevin A and Coburn, Bryan and Hernandez, Alejandro and Langford, Bradley J and Leung, Valerie and MacFadden, Derek and Rooney, Ashley M and Schwartz, Kevin L and Daneman, Nick},
  title = {Antibiotic and Nonantibiotic Drugs Associated With Clostridioides difficile Infection Risk: a Pharmacopoeia-Wide Case-Cohort Study},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag001}
}
Kostenlos starten →